Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 10, 2015, Pages 1505-1519

  Koinis, Filippos ^a   Nintos, George ^a   Georgoulias, Vassilis ^a   Kotsakis, Athanasios ^a  

^a Hellenic Oncology Research Group (HORG)   (Greece)

Author keywords

Antibiotics; Chemotherapy induced; Epidemiology; G CSF; Neutropenia; Pathophysiology; Prevention; Prophylaxis; Risk assessment

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR;

ALTERNATIVE MEDICINE; ANTIBIOTIC THERAPY; CHEMOTHERAPY INDUCED NEUTROPENIA; COCHRANE LIBRARY; FEBRILE NEUTROPENIA; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; INFORMATION RETRIEVAL; LOW RISK PATIENT; MEDLINE; MICROBIOLOGICAL EXAMINATION; NEUTROPENIA; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREVALENCE; PREVENTION; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; TREATMENT RESPONSE; AMBULATORY CARE; CHEMICALLY INDUCED; DRUG COMBINATION; NEOPLASMS; QUALITY OF LIFE; RISK;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FEBRILE NEUTROPENIA; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; NEUTROPENIA; QUALITY OF LIFE; RISK;

EID: 84933529205     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1055248     Document Type: Review

References (103)

1. Plenderleith IH. Treating the treatment: toxicity of cancer chemotherapy. Can Fam Physician 1990; 36: 1827-30
2. Repetto L. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Crit Rev Oncol Hematol 2009; 72: 170-9
3. Pizzo PA. Management of fever in patients with cancer and treatmentinduced neutropenia. N Engl J Med 1993; 328: 1323-32
4. Khan S, Dhadda A, Fyfe D, et al. Impact of neutropenia on delivering planned chemotherapy for solid tumours. Eur J Cancer Care (Engl) 2008; 17: 19-25
5. Daniel D, Crawford J. Myelotoxicity from chemotherapy. Semin Oncol 2006; 33: 74-85
6. Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010; 116: 5555-63
7. Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Canc Netw 2015; 13: e1-7
8. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). National Cancer Institute. Available from: http: // healthcaredeliverycancergov/proctcae/ 2013
9. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Available from: http: //evs.nci.nih.gov/ftp1/CTCAE/ CTCAE-4.03-2010-06-14- QuickReference-5x7.pdf [Assessed at 17 January 2015]
10. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40
11. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135: 715-19
12. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52: e56-93
13. Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284: 1061-5
14. Gregory AD, Houghton AM. Tumor-Associated neutrophils: new targets for cancer therapy. Cancer Res 2011; 71: 2411-16
15. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228-37
16. Blijlevens NM, Logan RM, Netea MG. The changing face of febrile neutropeniafrom monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis. J Antimicrob Chemother 2009; 63(Suppl 1): i36-40
17. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14: 1201-7
18. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994; 97: 256-64
19. Fanourgiakis P, Vekemans M, Georgala A, et al. Febrile neutropenia and Fusobacterium bacteremia: clinical experience with 13 cases. Support Care Cancer 2003; 11: 332-5
20. Katz JA, Wagner ML, Gresik MV, et al. Typhlitis. An 18-year experience and postmortem review. Cancer 1990; 65: 1041-7
21. Koransky JR, Stargel MD, Dowell VR Jr. Clostridium septicum bacteremia. Its clinical significance. Am J Med 1979; 66: 63-6
22. Nesher L, Rolston KV. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis 2013; 56: 711-17
23. Lakshmaiah KC, Abhayakumar SM, Shetty R, et al. Management of febrile neutropenia in solid organ malignancies following chemotherapy. J Cancer Res Ther 2014; 10: 540-3
24. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990; 161: 397-401
25. Teranishi H, Ohzono N, Inamura N, et al. Detection of bacteria and fungi in blood of patients with febrile neutropenia by real-Time PCR with universal primers and probes. J Infect Chemother 2015; 21(3): 189-93
26. Poyart C, Morand P, Buzyn A. Etiology of bacterial infections in febrile neutropenic patients: the role of the laboratory in the diagnosis. Presse Med 2004; 33: 460-6
27. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-10
28. Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 2014; 68: 321-31
29. Nesher L, Rolston KV. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 2014; 42: 5-13
30. Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000; 160: 501-9
31. Wood MJ. Viral infections in neutropenia-current problems and chemotherapeutic control. J Antimicrob Chemother 1998; 41(Suppl D): 81-93
32. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000; 5: 224-37
33. Wilson-Royalty M, Lawless G, Palmer C, et al. Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature. J Oncol Pharm Pract 2002; 7: 141-7
34. Alexandre J, Gross-Goupil M, Falissard B, et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 2003; 14: 36-41
35. Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 2006; 14: 901-9
36. Hosmer W, Malin J, Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 2011; 19: 333-41
37. Crawford J, Glaspy JA, Stoller RG, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther 2005; 3: 36-46
38. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-51
39. Rondinelli PI, Ribeiro Kde C, De Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol 2006; 28: 665-70
40. Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003; 88: 181-6
41. Lalami Y, Paesmans M, Muanza F, et al. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors?. A retrospective analysis. Ann Oncol 2006; 17: 507-14
42. Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol 2014; 90: 190-9
43. Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011; 117: 1917-27
44. Laskey RA, Poniewierski MS, Lopez MA, et al. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecol Oncol 2012; 125: 625-30
45. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colonystimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-70
46. McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28: 3227-33
47. Okishiro M, Kim SJ, Tsunashima R, et al. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/ cyclophosphamide. Breast Cancer Res Treat 2012; 132: 947-53
48. Vulsteke C, Lambrechts D, Dieudonne A, et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 2013; 24: 1513-25
49. Van Der Bol JM, De Jong FA, Van Schaik RH, et al. Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia. Oncologist 2010; 15: 1063-72
50. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31: 794-810
51. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009; 7: 99-108
52. Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-Analysis. BMC Cancer 2011; 11: 404
53. Bennett CL, Djulbegovic B, Norris LB, et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013; 368: 1131-9
54. Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2012; 10: 1412-45
55. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32
56. Renner P, Milazzo S, Liu JP, et al. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev 2012; 10: CD007913
57. Dale DC. Advances in the treatment of neutropenia. Curr Opin Support Palliat Care 2009; 3: 207-12
58. Gafter-Gvili A, Fraser A, Paul M, et al. Meta-Analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-95
59. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006; 107: 1743-51
60. Timmer-Bonte JN, De Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colonystimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005; 23: 7974-84
61. Garnica M, Nouer SA, Pellegrino FL, et al. Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infect Dis 2013; 13: 356
62. Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy-EORTC infectious diseases group trial XV. J Clin Oncol 2013; 31: 1149-56
63. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, et al. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 2009; CD006706
64. Cheuk DK, Chiang AK, Lee TL, et al. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev 2011; CD006505
65. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010; 28: 2481-90
66. De Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21(Suppl 5): v252-6
67. Paesmans M, Klastersky J. Risk Assessment in Adult Cancer Patients with Febrile Neutropenia: A Review of Methods and of Risk-Adapted Empiric Treatments. Hosp Chronicles 2007; 2: 66-73
68. Teuffel O, Ethier MC, Alibhai SM, et al. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-Analysis. Ann Oncol 2011; 22: 2358-65
69. Innes H, Marshall E. Outpatient therapy for febrile neutropenia. Curr Opin Oncol 2007; 19: 294-8
70. Talcott JA, Yeap BY, Clark JA, et al. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol 2011; 29: 3977-83
71. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60
72. Malik IA, Khan WA, Karim M, et al. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995; 98: 224-31
73. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006; 24: 4129-34
74. Sebban C, Dussart S, Fuhrmann C, et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 2008; 16: 1017-23
75. Cherif H, Johansson E, Bjorkholm M, et al. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 2006; 91: 215-22
76. Minotti V, Gentile G, Bucaneve G, et al. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 1999; 7: 134-9
77. Freifeld A, Sankaranarayanan J, Ullrich F, et al. Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer 2008; 16: 181-91
78. Cameron D. Management of chemotherapy-Associated febrile neutropenia. Br J Cancer 2009; 101(Suppl 1): S18-22
79. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51
80. Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res 2014; 14: 162
81. Prevention and Treatment of Cancer-Related Infections. National Comprehensive Cancer Network (NCCN), Version 22014. 2014. Available from: https: // wwwnccnorg/store/login/loginaspx?. ReturnURL=http%3a%2f% 2fwwwnccnorg%2fprofessionals% 2fphysician-gls%2fpdf%2finfectionspdf
82. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 2012; 33: 322-7
83. Zhang S, Wang Q, Ling Y, et al. Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer. BMC Cancer 2015; 15: 42
84. Yagci D, Yoruk F, Azap A, et al. Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy. Antimicrob Agents Chemother 2009; 53: 1287-9
85. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-11
86. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341: 312-18
87. Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-Aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev 2013; 6: CD003038
88. Vidal L, Ben Dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2013; 10: CD003992
89. Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014; 10: CD003039
90. Vellenga E, Uyl-de Groot CA, De Wit R, et al. Randomized placebo-controlled trial of granulocyte-macrophage colonystimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996; 14: 619-27
91. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93: 31-8
92. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013; 98: 1826-35
93. Slobbe L, Waal L, Jongman LR, et al. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study. Eur J Cancer 2009; 45: 2810-17
94. Hodgson-Viden H, Grundy PE, Robinson JL. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr 2005; 5: 10
95. Jorgensen KJ, Gotzsche PC, Dalboge CS, et al. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. Cochrane Database Syst Rev 2014; 2: CD004707
96. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000; 18: 1412-22
97. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Contr 2001; 8: 1-25.quiz 27-8
98. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101: 3840-8
99. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23: 1178-84
100. Balducci L, Cohen HJ, Engstrom PF, et al. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005; 3: 572-90
101. Van Dalen EC, Mank A, Leclercq E, et al. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev 2012; 9: CD006247
102. Pais I, Correia N, Pimentel I, et al. Effects of acupuncture on leucopenia, neutropenia, NK, and B cells in cancer patients: a randomized pilot study. Evid Based Complement Alternat Med 2014; 2014: 217397
103. Choi TY, Lee MS, Ernst E. Moxibustion for the treatment of chemotherapyinduced leukopenia: a systematic review of randomized clinical trials. Support Care Cancer 2015; 23(6): 1819-26